Project Grant R44CA247110

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...

The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $818,360 Cooperative Agreement to the University of Southern California (USC) to develop new highly potent and safe Angiotensin AT2 receptor (AT2R) antagonists for the treatment of neuropathic pain. This 4-year project aims to optimize a novel lead series of AT2R antagonists that have demonstrated better potency and...

The National Cancer Institute (NCI) awarded a $179,403 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Nebraska Medical Center (UNMC) to develop and screen novel flupirtine analogue compounds as non-opioid analgesics for treating chemotherapy-induced neuropathic pain (CINP). The 2-year project aims to synthesize and evaluate flupirtine analogues that can effectively relieve CINP while mitigating the liver toxicity concerns associated with the parent...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This $407,113 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to develop new potassium channel modulators to reduce neuronal overexcitation and mitigate chronic pain. The award, granted to the University of California, Irvine, funds research to identify and validate compounds that can stabilize the interaction between potassium channels...

This $3,892,145 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is funding research under the NIH Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of succinate signaling for pain relief in oral cancer. The primary objective is to determine if inhibiting the succinate receptor SUCNR1 can alleviate oral cancer pain by reducing inflammation and nociception (pain...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $650,079 Project Grant to Northeastern University under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports the development and optimization of novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) subunit, with the goal of exploring its potential for pain management. The 5-year project aims to advance...

This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...